Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tandem Diabetes Care's change in inventory for the quarter that ended in Jun. 2026 was $-10 Mil. It means Tandem Diabetes Care's inventory
increased by $10 Mil
from Mar. 2026 to Jun. 2026 .
Tandem Diabetes Care's change in inventory for the fiscal year that ended in Dec. 2025 was $25 Mil. It means Tandem Diabetes Care's inventory
declined by $25 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Tandem Diabetes Care's Days Inventory for the quarter that ended in Jun. 2026 was 108.68.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Tandem Diabetes Care's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.84.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tandem Diabetes Care's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.51.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tandem Diabetes Care's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Change In Inventory Related Terms
Tandem Diabetes Care Change In Inventory Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (TNDM) has a Change In Inventory of $4 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Change In Inventory too high?
Tandem Diabetes Care's current Change In Inventory is $4 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Change In Inventory compare to AVNS and IRMD?
Tandem Diabetes Care's Change In Inventory of $4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Devices & Instruments company?
A good Change In Inventory depends on the Medical Devices & Instruments industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Change In Inventory is $4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (TNDM) is currently considered Fairly Valued. The stock's GF Value™ is $24.16, compared to a current price of $22.81 — trading 5.6% below its estimated fair value. The current Change In Inventory is $4 Mil. Tandem Diabetes Care's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Tandem Diabetes Care (TNDM), the current Change In Inventory is $4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $22.81 is trading 5.6% below its estimated GF Value™ of $24.16.
GuruFocus considers Tandem Diabetes Care to be Fairly Valued.
Key valuation signals for TNDM:
Change In Inventory: $4 Mil
GF Value™: $24.16 vs. price of $22.81 (5.6% below fair value)
No single metric tells the full story. See the TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
73GF Score
Get the complete analysis for TNDM
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNDM has been successfully added to your 
